Joachim Wernicke

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment
    Joachim F Wernicke
    Lilly Research Laboratories, Indianapolis IN 46285, USA
    J Clin Psychopharmacol 24:30-5. 2004
  2. ncbi Safety and side effect profile of fluoxetine
    Joachim F Wernicke
    Lilly Corporate Center, Indianapolis, IN 46285, USA
    Expert Opin Drug Saf 3:495-504. 2004
  3. ncbi The placebo response in pain and depression: in search of a common pathway
    Joachim F Wernicke
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Front Biosci (Schol Ed) 2:106-11. 2010
  4. doi Safety and tolerability of duloxetine treatment of diabetic peripheral neuropathic pain between patients with and without cardiovascular conditions
    Joachim F Wernicke
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Diabetes Complications 23:349-59. 2009
  5. ncbi Hepatic effects of duloxetine-III: analysis of hepatic events using external data sources
    Indiana Strombom
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Drug Saf 3:154-62. 2008
  6. ncbi Hepatic effects of duloxetine-II: spontaneous reports and epidemiology of hepatic events
    Joachim Wernicke
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    Curr Drug Saf 3:143-53. 2008
  7. ncbi Hepatic effects of duloxetine-I: non-clinical and clinical trial data
    Joachim Wernicke
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    Curr Drug Saf 3:132-42. 2008
  8. ncbi An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain
    Joachim F Wernicke
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Pain Med 8:503-13. 2007
  9. ncbi An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies
    Joachim Wernicke
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Drug Saf 30:437-55. 2007
  10. ncbi A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain
    J F Wernicke
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Neurology 67:1411-20. 2006

Detail Information

Publications24

  1. ncbi Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment
    Joachim F Wernicke
    Lilly Research Laboratories, Indianapolis IN 46285, USA
    J Clin Psychopharmacol 24:30-5. 2004
    ..It appears that atomoxetine may be discontinued without risk for symptom rebound or discontinuation-emergent adverse effects. Tapering of doses is not necessary when atomoxetine is discontinued...
  2. ncbi Safety and side effect profile of fluoxetine
    Joachim F Wernicke
    Lilly Corporate Center, Indianapolis, IN 46285, USA
    Expert Opin Drug Saf 3:495-504. 2004
    ..However, most of these are not clinically important. The purpose of this review is to provide an overview of some of the most important information related to safety and side effects of this drug...
  3. ncbi The placebo response in pain and depression: in search of a common pathway
    Joachim F Wernicke
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Front Biosci (Schol Ed) 2:106-11. 2010
    ..Placebo-related responses to both analgesia and relief from depression were reported to be associated with an increase in activity in the frontal cortex and a decrease in activity in the thalamus...
  4. doi Safety and tolerability of duloxetine treatment of diabetic peripheral neuropathic pain between patients with and without cardiovascular conditions
    Joachim F Wernicke
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Diabetes Complications 23:349-59. 2009
    ..We compared the safety of duloxetine in patients with (CV-positive) and without (CV-negative) historical/comorbid cardiovascular conditions at study entry...
  5. ncbi Hepatic effects of duloxetine-III: analysis of hepatic events using external data sources
    Indiana Strombom
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Drug Saf 3:154-62. 2008
    ..Present results from two hepatic safety studies conducted within 20 months after duloxetine launch...
  6. ncbi Hepatic effects of duloxetine-II: spontaneous reports and epidemiology of hepatic events
    Joachim Wernicke
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    Curr Drug Saf 3:143-53. 2008
    ..Review spontaneous reports and epidemiology of hepatic events associated with duloxetine...
  7. ncbi Hepatic effects of duloxetine-I: non-clinical and clinical trial data
    Joachim Wernicke
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    Curr Drug Saf 3:132-42. 2008
    ..Review nonclinical and clinical trial data for hepatic effects of duloxetine...
  8. ncbi An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain
    Joachim F Wernicke
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Pain Med 8:503-13. 2007
    ..To assess the safety of duloxetine at a fixed-dose of 60 mg twice daily (BID) for up to 52 weeks, and compare duloxetine with routine care in the management of patients with diabetic peripheral neuropathic pain (DPNP)...
  9. ncbi An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies
    Joachim Wernicke
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Drug Saf 30:437-55. 2007
    ..This study was designed to evaluate the cardiovascular safety profile of the SNRI duloxetine through evaluation of cardiovascular-related parameters and adverse events (AEs)...
  10. ncbi A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain
    J F Wernicke
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Neurology 67:1411-20. 2006
    ..Serotonin (5-HT) and norepinephrine (NE) are involved in pain modulation via descending inhibitory pathways in the brain and spinal cord...
  11. ncbi Safety and adverse event profile of duloxetine
    Joachim F Wernicke
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Expert Opin Drug Saf 4:987-93. 2005
    ..The purpose of this review is to provide an overview of some of the most important information related to safety and tolerability of duloxetine...
  12. ncbi Cardiovascular effects of atomoxetine in children, adolescents, and adults
    Joachim F Wernicke
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    Drug Saf 26:729-40. 2003
    ..Adverse effects on the cardiovascular system, including abnormalities in heart rate, blood pressure, or cardiac rhythm have been associated with several noradrenergic medications...
  13. ncbi A retrospective pooled analysis of duloxetine safety in 23,983 subjects
    James Gahimer
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Med Res Opin 23:175-84. 2007
    ..The objective of this manuscript is to characterize the overall safety profile of duloxetine, regardless of indication, based on data from the duloxetine exposures integrated safety database...
  14. ncbi Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies
    David Michelson
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Biol Psychiatry 53:112-20. 2003
    ..To assess the efficacy of atomoxetine, a new and highly selective inhibitor of the norepinephrine transporter, we conducted two large, multicenter treatment trials...
  15. ncbi Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study
    David Michelson
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Am J Psychiatry 159:1896-901. 2002
    ..The authors assessed the efficacy of once-daily atomoxetine administration in the treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD)...
  16. doi Answers to the most common questions about the hepatic safety profile of duloxetine
    Madelaine M Wohlreich
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Postgrad Med 120:111-8. 2008
    ..Therefore, it does not warrant hepatic enzyme monitoring. As with any medication, physicians should follow prescribing guidelines and educate patients on the risks and benefits of duloxetine...
  17. ncbi Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder
    Mark E Bangs
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Drug Saf 31:345-54. 2008
    ..This study describes and assesses potential hepatobiliary events related to atomoxetine therapy, as reported in clinical trials and as spontaneous adverse event reports post-launch in 2002...
  18. ncbi Detecting treatment emergent adverse events in clinical trials : a comparison of spontaneously reported and solicited collection methods
    Joachim F Wernicke
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Drug Saf 28:1057-63. 2005
    ..The objective of this analysis is to compare the reporting rates and the ability to detect drug-placebo differences with spontaneous versus solicited adverse event collection methods...
  19. ncbi A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain
    Joel Raskin
    Lilly Research Laboratories, Eli Lilly Canada, Toronto, Ontario, Canada
    Pain Med 6:346-56. 2005
    ..Assess efficacy and safety of duloxetine, a selective serotonin and norepinephrine reuptake inhibitor, on the reduction of pain severity, in patients with diabetic peripheral neuropathic pain (DPNP)...
  20. ncbi Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine
    Joachim F Wernicke
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA
    Dev Med Child Neurol 49:498-502. 2007
    ..The shared vulnerability between ADHD and seizure activity should be taken into account when making treatment decisions for populations of children with epilepsy and children with ADHD...
  21. ncbi QT correction methods in children and adolescents
    Joachim F Wernicke
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    J Cardiovasc Electrophysiol 16:76-81. 2005
    ..Previous work suggests the most appropriate correction formula for adults is QTc=QT/RR0.40, but little on correction methods for children and adolescents has been published...
  22. ncbi Duloxetine for the treatment of fibromyalgia in women: pooled results from two randomized, placebo-controlled clinical trials
    Lesley M Arnold
    Women s Health Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45219, USA
    J Womens Health (Larchmt) 16:1145-56. 2007
    ....
  23. ncbi A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder
    Lesley M Arnold
    Women s Health Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45219, USA
    Pain 119:5-15. 2005
    ..In conclusion, both duloxetine 60 mg QD and duloxetine 60 mg BID were effective and safe in the treatment of fibromyalgia in female patients with or without major depressive disorder...